(Los Gatos, California) – Venova Medical, Inc. (Venova Medical), a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access today announced that it will present an oral abstract reporting the results of the VENOS-1 study at the American Society of Nephrology’s Kidney Week behing held in San Diego from October 24th to October 27th 2024. The VENOS-1 trial (NCT 05757726) is a prospective, single-arm, early feasibility study of the Venova Medical’s VelocityTM pAVF System, an innovative medical technology being developed to use a minimally invasive technique to create an arterio-venous fistula (AVF) for hemodialysis vascular access. The Velocity pAVF System is designed to provide optimal and durable fistula flow to support maturation and clinical use for hemodialysis. The percutaneous procedure is designed to be performed in an office, surgery center or outpatient hospital setting.
Details of the presentation are as follow:
Presentation Title: Midterm Outcomes of a Novel First-in-Human Percutaneous Arteriovenous Fistula
Session Name: Dialysis Vascular Access: Research Advances
Session Date: Saturday, October 26, 2024
Presentation Time: 05:40 PM – 05:50 PM
Location: Room 8, San Diego Convention Center
Presenter: Dirk Hentschel, MD, Brigham and Women’s Hospital, Boston, Massachusetts, United States
CLICK HERE to view the abstract